Mind Medicine (MindMed) Inc. (MNMD)

NASDAQ: MNMD · IEX Real-Time Price · USD
9.53
-0.35 (-3.54%)
At close: Apr 17, 2024, 4:00 PM
9.56
+0.03 (0.31%)
After-hours: Apr 17, 2024, 7:59 PM EDT
-3.54%
Market Cap 671.87M
Revenue (ttm) n/a
Net Income (ttm) -95.73M
Shares Out 70.50M
EPS (ttm) -2.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 775,782
Open 9.94
Previous Close 9.88
Day's Range 9.49 - 10.05
52-Week Range 2.41 - 12.22
Beta 2.53
Analysts Strong Buy
Price Target 30.17 (+216.58%)
Earnings Date May 2, 2024

About MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 57
Stock Exchange NASDAQ
Ticker Symbol MNMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for MNMD stock is "Strong Buy." The 12-month stock price forecast is $30.17, which is an increase of 216.58% from the latest price.

Price Target
$30.17
(216.58% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

MindMed to Present at Upcoming April Medical Conferences

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product...

15 days ago - Business Wire

MindMed Announces Voluntary Delisting from Cboe Canada

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product c...

16 days ago - Business Wire

MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product c...

5 weeks ago - Business Wire

PLTR, MNMD, ODD: Finding Value in the Market

Hilary Kramer discusses finding value in the market. She talks about her stock picks which include Palantir (PLTR), Mind Medicine (MNMD), Oddity (ODD), Prairie Operating (PROP), Starbucks (SBUX), and ...

Other symbols: ODDPLTR
5 weeks ago - Schwab Network

Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder

VANCOUVER, BC , March 8, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral...

5 weeks ago - PRNewsWire

Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product c...

5 weeks ago - Business Wire

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product ...

5 weeks ago - Business Wire

MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product...

6 weeks ago - Business Wire

MindMed Reports 2023 Financial Results and Business Updates

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product c...

7 weeks ago - Business Wire

MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product c...

7 weeks ago - Business Wire

MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product c...

2 months ago - Business Wire

MindMed Announces Business Update and Anticipated Milestones for 2024

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to tre...

3 months ago - Business Wire

Why one backer of MDMA therapy sees ‘exponential' growth following FDA approval this year

A financial backer of an effort to legalize the drug MDMA for therapeutic use sees the potential for “exponential growth” should it win approval from the U.S. Food and Drug Administration, possibly ov...

Other symbols: CMPSJNJ
3 months ago - Market Watch

MindMed announces positive results in trial of LSD as a treatment for generalized anxiety disorder

Mind Medicine Inc. MNMD, +3.53% said Thursday a Phase 2 trial testing LSD as a treatment for generalized anxiety disorder met its main goal, showing a statistically significant improvement in scores b...

4 months ago - Market Watch

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candida...

4 months ago - Business Wire

MindMed Reports Third Quarter 2023 Financial Results and Business Highlights

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed today reported its financial results for the quarter ended September 30, 2023.

5 months ago - Business Wire

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET.

6 months ago - Business Wire

MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

NEW YORK--(BUSINESS WIRE)---- $MNMD--Enrollment completed for MMED007, the Phase 2a study evaluating repeated low-dose administration of MM-120 for the treatment of adults with ADHD.

6 months ago - Business Wire

MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data for MM-402 in a model for autism spectrum disorder.

7 months ago - Business Wire

MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit.

7 months ago - Business Wire

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed has completed enrollment and dosing in Study MMED008, the Phase 2b study evaluating MM-120 (lysergide D-tartrate) for the treatment of GAD.

7 months ago - Business Wire

MindMed to Participate at September Investor Conferences

NEW YORK--(BUSINESS WIRE)---- $MNMD--The MindMed management team will participate in two September investor conferences.

8 months ago - Business Wire

MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed has entered into a senior secured credit facility with K2 HealthVentures, a healthcare-focused specialty finance company.

8 months ago - Business Wire

MindMed Reports Second Quarter 2023 Financial Results and Business Highlights

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed today reported its financial results for the quarter ended June 30, 2023.

9 months ago - Business Wire

MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed has entered into a license agreement to access Catalent's proprietary Zydis® orally disintegrating tablet (ODT) technology.

9 months ago - Business Wire